HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 483-490

  Sangiuolo, Federica ^a   Puxeddu, Ermanno ^a   Pezzuto, Gabriella ^b   Cavalli, Francesco ^a   Longo, Giuliana ^a   Comandini, Alessia ^b   Di Pierro, Donato ^a   Pallante, Marco ^a   Sergiacomi, Gianluigi ^b   Simonetti, Giovanni ^b   Zompatori, Maurizio ^c   Orlandi, Augusto ^a   Magrini, Andrea ^a   Amicosante, Massimo ^a   Mariani, Francesca ^d   Losi, Monica ^b   Fraboni, Daniela ^b   Bisetti, Alberto ^e   Saltini, Cesare ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CNR   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; DICHLORODIHYDROFLUORESCEIN DIACETATE; HEMOSIDERIN; HFE PROTEIN; IRON; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; OXYGEN;

ADULT; AGED; ARTICLE; BASOPHIL; CONTROLLED STUDY; DOT HYBRIDIZATION; EOSINOPHIL; FEMALE; FIBROSING ALVEOLITIS; FLUOROMETRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOCHROMATOSIS; HFE GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; LUNG LAVAGE; LYMPHOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; RISK FACTOR; STAINING; TOTAL LUNG CAPACITY; WILD TYPE; ALLELE; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; CHEMISTRY; GENETIC VARIATION; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED;

ADULT; ALLELES; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUOROMETRY; GENETIC VARIATION; HEMOCHROMATOSIS; HEMOSIDERIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; IRON; MACROPHAGES; MALE; MALONDIALDEHYDE; MEMBRANE PROTEINS; MIDDLE AGED; OXYGEN; REACTIVE OXYGEN SPECIES;

EID: 84950170987     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104814     Document Type: Article

References (43)

1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
3. Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 2008;39:1275-1294.
4. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 1984;310:154-166.
5. Strausz J, Müller-Quernheim J, Steppling H, et al. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990;141:124-128.
6. Rahman I, Skwarska E, Henry M, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 1999;27:60-68.
7. Burger RM, Peisach J, Horwitz SB. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 1981;256:11636-11644.
8. Chandler DB, Barton JC, Briggs DD 3rd, et al. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis 1988;137:85-89.
9. Pinho RA, Silveira PC, Silva LA, et al. N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure. Environ Res 2005;99:355-360.
10. Kim KH, Maldonado F, Ryu JH, et al. Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Res 2010;11:37.
11. Puxeddu E, Comandini A, Cavalli F, et al. Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage? Pulm Pharmacol Ther 2014;28:35-40.
12. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990;11:127-137.
13. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-1477.
14. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218.
15. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
16. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-623.
17. Tomatsu S, Orii KO, Fleming RE, et al. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc Natl Acad Sci USA 2003;100:15788-15793.
18. Njajou OT, Houwing-Duistermaat JJ, Osborne RH, et al. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum Genet 2003;11:225-231.
19. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-278.
20. Costa-Matos L, Batista P, Monteiro N, et al. Hfe mutations and iron overload in patients with alcoholic liver disease. Arq Gastroenterol 2013;50:35-41.
21. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-342.
22. Thompson AB, Bohling T, Heires A, et al. Lower respiratory tract iron burden is increased in association with cigarette smoking. J Lab Clin Med 1991;117:493-499.
23. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-1152.
24. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-1014.
25. Golde DW, Drew WL, Klein HZ, et al. Occult pulmonary haemorrhage in leukaemia. Br Med J 1975;2:166-168.
26. Lazzarino G, Di Pierro D, Tavazzi B, et al. Simultaneous separation of malondialdehyde, ascorbic acid, and adenine nucleotide derivatives from biological samples by ion-pairing high-performance liquid chromatography. Anal Biochem 1991;197:191-196.
27. Esterbauer H, Lang J, Zadravec S, et al. Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol 1984;105:319-328.
28. Bass DA, Parce JW, Dechatelet LR, et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983;130:1910-1917.
29. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies (STREGA) - an extension of the STROBE statement. Eur J Clin Invest 2009;39:247-266.
30. Persson HL, Vainikka LK, Eriksson HB, et al. Lane-Hamilton syndrome: ferritin protects lung macrophages against iron and oxidation. Chest 2011;139:361-367.
31. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009;33:189-200.
32. Maldonado F, Parambil JG, Yi ES, et al. Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J 2009;33:1361-1366.
33. Priftis KN, Anthracopoulos MB, Tsakanika C, et al. Quantification of siderophages in bronchoalveolar fluid in transfusional and primary pulmonary hemosiderosis. Pediatr Pulmonol 2006;41:972-977.
34. Khong PL, Chan GC, Lee SL, et al. Beta-thalassemia major: thin-section CT features and correlation with pulmonary function and iron overload. Radiology 2003;229:507-512.
35. Ooi GC, Khong PL, Lam WK, et al. Pulmonary iron overload in thalassemia major presenting as small airway disease. Acta Haematol 2002;108:43-46.
36. Ghoti H, Fibach E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010;95:1433-1434.
37. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 2000;152:307-315.
38. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519.
39. Floreani A, Rosa Rizzotto E, Basso D, et al. An open population screening study for HFE gene major mutations proves the low prevalence of C282Y mutation in Central Italy. Aliment Pharmacol Ther 2007;26:577-586.
40. Agabiti N, Porretta MA, Bauleo L, et al. Idiopathic pulmonary fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:191-197.
41. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66:462-467.
42. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:729-737.
43. Morlá M, Busquets X, Pons J, et al. Telomere shortening in smokers with and without COPD. Eur Respir J 2006;27:525-528.